Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab.

ABSTRACT:

Background

Triple negative breast cancer (TNBC) remains the most challenging breast cancer subtype so far. Specific therapeutic approaches have rarely achieved clinical improvements in treatment of TNBC patients and effective molecular biomarkers are largely unknown.

Methods

We used paired TNBC samples and high throughput RNA sequencing to identify differentially expressed circRNAs. Sucrose gradient polysome fractionation assay, antibody and Mass spectra were used to validate active circRNA translation. The novel protein function was validated in vitro and in vivo by gain or loss of function assays. Mechanistic results were concluded by immunoprecipitation analyses and kinase activity assay.

Results

Circular HER2 RNA (circ-HER2) encoded a novel protein, HER2-103. Unex

SUBMITTER: Li J 

PROVIDER: S-EPMC7488427 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature